Going Global with Gilead Sciences Inc.

Simon Bonouvrie

Cadence Capital

Gilead Sciences (NASDAQ: GILD) was the first offshore position in the Cadence portfolio, initiated in mid-2014. We initiated the position at a price of approx US$82 and have added to the stock since then. The stock is currently US$122. Gilead is a large US biotech stock specialising in antiviral drugs to treat patients suffering from HIV, hepatitis C, influenza and other medical conditions. Gilead's market capitalisation is US$180b, making it larger than any company listed on the ASX. Read more here (VIEW LINK)

Simon joined Cadence Capital in 2013 as a Portfolio Manager. Prior to joining Cadence, Simon was a Portfolio Manager at Platypus Asset Management for 8 years. After completing a Bachelor of Engineering (Chemical) (Honours), Bachelor of Commerce...


No areas of expertise

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.